Table 3 Drug therapy according to neprilysin levels, at baseline and at follow-up
Overall (n = 68) | Neprilysin level ≤ 125 pg/mL (n = 38) | Neprilysin level 126–450 pg/mL (n = 15) | Neprilysin level > 450 pg/mL (n = 15) | Overall p.value | Highest-level vs. lower groups p.value | |
|---|---|---|---|---|---|---|
At baseline | ||||||
antiplatelet agent | 6 (8.8%) | 2 (5.3%) | 1 (6.7%) | 3 (20.0%) | 0.23 | 0.23 |
beta-blocker | 3 (4.4%) | 2 (5.3%) | 0 | 1 (6.7%) | 0.63 | 1 |
ACEI/ARB/MRA | 18 (26.5%) | 8 (21.1%) | 5 (33.3%) | 5 (33.3%) | 0.53 | 0.73 |
statins | 17 (25.0%) | 9 (23.7%) | 4 (26.7%) | 4 (26.7%) | 0.97 | 1 |
diuretics | 7 (10.3%) | 3 (7.9%) | 2 (13.3%) | 2 (13.3%) | 0.77 | 1 |
At follow-up | ||||||
antiplatelet agent | 68 (100.0%) | 38 (100.0%) | 15 (100.0%) | 15 (100.0)% | – | |
beta-blocker | 64 (94.1%) | 36 (94.7%) | 14 (93.3%) | 14 (93.3%) | 0.98 | 1 |
ACEI/ARB/MRA | 52 (76.5%) | 30 (78.9%) | 12 (80.0%) | 10 (66.7%) | 0.60 | 0.51 |
statins | 65 (95.6%) | 37 (97.4%) | 15 (100.0%) | 13 (86.7%) | 0.15 | 0.24 |
diuretics | 11 (16.2%) | 7 (18.4%) | 2 (13.3%) | 2 (13.3%) | 0.86 | 1 |